Variations of angioarchitecture of the liver malignant tumors and its influence on the choice of the microspheres diameter.

Варианты ангиоархитектоники злокачественных новообразований печени и ее влияние на возможность выбора диаметра микросфер.
Turlybek Tuganbekov 1, Nasrulla Shanazarov 1 2, Niyaz Malayev 3
More Detail
1 Astana Medical University, Department of surgery, Kazakhstan
2 Medical center of affairs of the President, Department of surgery, Astana, Kazakhstan
3 National Scientific Center of Oncology and Transplantation, Department of surgery, Astana, Kazakhstan
J CLIN MED KAZ, Volume 4, Issue 38, pp. 6-11.
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

The review deals with one of the topical issues of modern oncology: treatment of patients with unresectable liver cancer. The possibilities of a common endovascular treatment - hepatic artery chemoembolization (TACE). A comparison of the properties of the most used saturated microspheres (Hepasphere, Ds Bead, Tandem), describes the options angioarchitectonics tumors and the possibility of using the microspheres according to the blood supply.

CITATION

Tuganbekov T, Shanazarov N, Malayev N. Variations of angioarchitecture of the liver malignant tumors and its influence on the choice of the microspheres diameter.. Journal of Clinical Medicine of Kazakhstan. 2015;4(38):6-11.

REFERENCES

  • Bazin I.S. Hepatocellular cancer - a current state of a problem, Practical oncology, 2008, 9(4), pp. 216-228.
  • Granov A.M., Davydova M. I. Intervencionnaya radiologiya v onkologii (Intervention radiology in oncology. Ways of development and technology: scientific and practical), SPb: 2013, 342 р.
  • Dolgushin B.I., Virshke E.R. et al. Rentgen endovaskulyarnoe lechenie pacientov s neoperabel’nym gepatotsellyulyarnym rakom(Endovascular treatment of the patients with an inoperable Hepatocellular cancer), Annals of surgical hepatology, 2010, T.14, No. 4, pp.18-23.
  • Davydov M.I., Axel E.M. Statistika zlocachestvennyh novoobrazovaniy v Rossii I stranah SNG (The statistic of malignant new growths in Russia and the CIS countries in 2012), the Russian oncological scientific center of N. N. Blochin, Moscow, 2014, 226 p.
  • Health of the population of the Republic of Kazakhstan and activity of the organizations of health care in 2013, Statistical collection, Astana, 2014,355 p.
  • Zdorov’e naseleniya respubliki Kazakstan v 2012 (Health of the population of the Republic of Kazakhstan and activity of the organizations of health care in 2012), Statistical collection, Astana, 2013, P. 251-254.
  • Malayev N.B. Vozmozhnosti rentgenendovaskulyarnykh vmeshatel’stv v lechenii ob’emnyh obrazovaniy pecheni (Opportunities the of interventions in diagnostics and treatment of volume formations of a liver). Vestnik Administration of the President RK, 2014, No. 2(55),pp. 68-71.
  • Merabishvili V.M, Merabishvili E.N., Chepik O.F. Rak pecheni. Epidemiologiya (Liver cancer epidemiology. Incidence, mortality, dynamics of histologic structure), Siberian oncological journal, 2015. No. 2, pp. 5-14.
  • Pocazateli oncologicheskoy sluzhby v RK (Indicators of oncological service RK for 2013), Statistical collection, Almaty 2014, P. 125.
  • Seryogin A.A. A X-ray endovascular himioembolization of a hepatic artery - a modern method of regionarny chemotherapy of malignant damages of a liver, Ukrainian surgical journal, 2014, No. 2, pp. 110-126.
  • Seryogin A.A., Zaytsev A.I., Sharabrin E.G. et al, Rentgenendovaskulyarnayahimioembolizaciyapechenochnoyarteriipripor azheniipecheni (X-ray endovascular hemoembolization of the hepatic artery at focal damages of a liver),Ukrainian surgical journal, No. 3 (22), 2013, pp. 25-31.
  • TarazovP.G. Rentgenendovaskulyarnye vmeshatel’ctva v lechenii pervichnogo raka pecheni (X-ray endovascular of intervention in treatment of primary cancer of liver), Practical oncology, 2008, T. 9, No. 4,pp. 209-215.
  • Tarazov P.G., Polikarpov A.A. Rentgen endovaskulyarnye vmeshatel’ctva v lechenii pervichnogo raka pecheni (X-ray endovascular of intervention in treatment of primary cancer of liver), Almanac to them A.V. Vishnevsky, 2010, T.5, No. 2,pp.7- 15.
  • Tarazov P.G., Polikarpov A.A., Granov D.A. Arterial’naya himioambolizaciya v lechenii bol’nyh s metastazami v pechen’ (An arterial hemoembolization in treatment of patients from of a malignant kartsionoid in a liver), the Annals surgical gepatologii, 2010, T.15, No. 3, pp. 23-28.
  • Tuganbekov T.U., Bohr S.P., Shanazarov N. A., Malayev N. B., Kaldybayev M.M. Varianty angioarhitectoniki pervichnyh I metastaticheskih novoobrazovaniy pecheni I ih vliyanie na rezultaty himioaembolizacii (Angioarkhtektonik options of primary and metastatic new growths of a liver and their influence on results of a himioembolization), the Materials of the congress «Actual problems of gepatopankreatobiliarny surgery», Tashkent, 2015, pp.188-189.
  • Tuganbekov T.U., Bor S.P., Shanazarov N.A., Malayev N.B. The role of angioarkhitektonik of new growths of a liver in a choice of a method of an endovascular hemoembolization, Astana Medical Journal, 2015, No. 3 (85), pp.13-21.
  • Tuganbekov T.U, Shanazarov N., MalayevN. B. Himioembolization of volume new growths of a liver taking into account features their angioarkhitektonik, the Siberian oncological journal, 2015.
  • Tuganbekov T.U., Shanazarov N.A., Bohr S.P., Malayev N.B. Himioembolization saturable microspheres of volume new growths of a liver taking into account features their angioarkhitektonik, the Collection of scientific works «The Nevsky radiological forum», St. Petersburg, 2015, pp. 712-714.
  • Shpak S.A., N.V.’s Momot, Tanasichuk-Gazhiyev N.V. et. al Features of a multislice computer tomography in differential diagnosis of primary malignant tumors of a liver, Novoutvorennya,2010,No. 2 (6), pp. 98-105.
  • Antonio B, Gianpaolo C. Anna M I, Elias B. Quality-Improvement Guidelines for hepatic transarterial сhemoembolization, Cardiovascular and Interventional Radiological Society of Europe (CIRSE), 2012.
  • Bastian P, Bartkowski R, Köhler H, et al. Chemoembolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of differentsizes in an animal model for the locoregional therapy, Eur.J Pharm Biopharm, 1998, No.46, pp.243-54.
  • Bilbao JI, de Luis E, García de Jalón JA, et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation, J. VascIntervRadiol, 2008, No.19, pp.1625-38.
  • Bonomo G, Pedicini V, Monfardini L et al. Bland embolization in patients with unresectable hepatocelllular carcinoma using precise, tightly sized calibrated antiinflammatory microparticles: first clinical experience and 1 year follow up.Cardio- vasc Intervent Radiol, 2010, No.33, pp.522–529.
  • Bonomo G, Pedicini V, Monfardini L. et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up, Cardio vasc Intervent Radiol, 2010, No. 33, pp.552–9.
  • Cruz JE, Saksena R, Jabbour SK, Nosher JL, et al .The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer, Ann Pharmacother, 2014, No. 48 (12), pp.23-25.
  • Katerina M, Maria P, Hippokratis M. Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30–60 lm. Safety and Efficacy Study, Cardio vasc Intervent Radiol, 2014, No.37, pp.165–175.
  • Cristina S., Guidi P., Pietro Q. Mario R., Serum Pharmacokinetics in Patients Treated with Transarterial Chemoembolization (TACE) UsingTwo Types of Epirubicin-loaded Microspheres, Anticancer research, 2012,No.32, pp.1769-1774.
  • Daniel M. Gnutzmann, MD, Anne S. et al. Evaluation of the Plasmatic and Parenchymal Elution Kinetics of Two Different Irinotecan-Loaded Drug-Eluting Embolics in a Pig Model, J Vasc Interv Radiol, 2015.
  • Dinca H, Pelage JP, Baylatry MT, Ghegediban SH, Pascale F, Manfait M et al. Why do small size doxorubicin-eluting microspheres induce more tissue necrosis than larger ones? A comparative study in healthy pig liver (oral communication 2206-2). CIRSE Annual meeting, Lisbon, 2012.
  • EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 2012, No.56 (4), pp.908-43.
  • Gadaleta C.D. Ranieri G.Transarterial chemoembolization as a therapy for liver tumors: New clinical developments and suggestions for combination with angiogenesis inhibitors, Crit. Rev. Oncol. Hematol, 2011,No. 80 (1), pp. 40-53.
  • Gonzalez MV, Tang Y, Phillips GJ, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro: in-vivo correlation, J Mater Sci Mater Med, 2008, No.19, pp.767-75.
  • Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol, 2008, No.31, pp.1141-9.
  • Gonzales VM, Tang Y, Phillips GJ, et al., Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro: in-vivo correlation, J Mater Sci Mater Med, 2008, No.19, pp.767–75. 
  • Jacques Blümmel, Sven Reinhardt, Markus Schäfer, Carl Gilbert, Lee Sun. Drug-eluting Beads in the Treatment of Hepatocellular Carcinomaand Colorectal Cancer Metastases to the Liver, European Oncology & Haematology, 2012, No.8 (3), pp.162–6.
  • Jacques B, Sven R, Markus S, Carl G, Lee S. Drug-eluting Beads in the Treatment of Hepatocellular Carcinoma and Colorectal Cancer Metastases to the Liver, European Oncology & Haematology, 2012, No.8(3), 162–166.
  • Jordan O, Denys A, De Baere T. et al. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphereloaded with doxorubicin and irinotecan, J. VascInterv. Radiol, 2010, No.21, pp.1084-90.
  • Jordan O, Denys A, De Baere T, et al., Comparative study of Chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan, J VascInterv Radiol, 2010, No.21, pp.1084–90.
  • Lewis AL, Dreher MR. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy, J Control Release, 2012 No.161(2), pp.338-50.
  • López-Benítez R, Richter GM, Kauczor HU, et al. Analysis of nontarget embolization mechanisms during embolization and chemoembolization procedures, Cardiovasc Intervent Radiol, 2009, No.32, pp.615-22.
  • Lewis AL, Gonzalez MV, Leppard SW, et al. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater SciMater Med, 2007, No.18, pp.1691-9.
  • Liapi, Eleni; Geschwind, Jean-Francois H. Chemoembolization for Primary and Metastatic Liver Cancer, The Cancer Journal, 2010, No.16 (2), pp. 156-162.
  • Lee Kh, Liapi e, Vossen JA, et al., Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with Mr imaging and implication for therapy, J VascIntervRadiol, 2008, No.19, pp. 1490–6.
  • Llovet JM1, BruixJ. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003, No.37(2), pp.429-42.
  • Lammer J1, Malagari K et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 2010, 33(1), pp.41-52.
  • Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarteria Chemoembolization of Unresectable Hepatocellular Carcinoma with DragEluting Beads: Results of an Open-Label Study of 62 Patients, Cardiovas Intervent Radiol, 2008, No.31, pp. 269-280.
  • Mao Y.M., Luo Z.Y., Li B., et al. Prospective study on the survival of HCC patients treated with transcatheter arterial lipiodol chemoembolization, Asian Pac J Cancer Prev, 2012, No.13(3), pp.1039-1042.
  • Malagari K, Alexopoulou E, Chatzimichail K et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead, Abdom Imaging, 2008,No.33(5), pp.512–519.
  • Martin R, Irurzun J, Munchart J, et al. Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose, Korean J Hepatol, 2011; 17:51–60.
  • Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis, World J Gastroenterol, 2014, No. 7; 20, pp.45.
  • Namur J, Wassef M, Millot JM, et al. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model, J VascIntervRadiol, 2010, No.21, pp.259–67.
  • Nikfarjam M, Muralidharan V, Malcontenti-Wilson C, Christophi C. Scanning electron microscopy study of the blood supply of human colorectal liver metastases, Eur J SurgOncol, 2003, No.29(10), pp.856-61.
  • Padia SA, Shivaram G, Bastawrous S. et al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small- versus medium-size particles, J VascIntervRadiol, 2013, 24(3), pp.301–306.
  • TakayasuK, ShimaY, MuramatsuY, MoriyamaN, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents, Radiology, 1987, No. 163, pp.345-351.
  • Sergio A1, Cristofori C, Cardin R, Pivetta G, Ragazzi R. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness, Am J Gastroenterol, 2008, No.103(4), pp.914-21.
  • She H.L, Burgmans M.C, Coenraadm M, Saraqueta A.F. In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma, Cardiovasc Intervent Radiol, 2015,No.18, pp.13- 17.
  • Yì-Xiáng J. Wáng, Thierry De Baere, Jean-Marc Idée. Transcatheter embolization therapy in liver cancer: an update of clinical evidences, Chinese Journal of Cancer Research, 2015, No. 27(2), pp.96-121.
  • Wang WD Ni JY, Xu LF, Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis, World J Gastroenterol, 2014, No. 7; 20(45), pp.17206-17.
  • Seck A, Rao PP, Pascale F, Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model, Cardiovasc Intervent Radiol. 2012, No. 35(6), pp.1448-59.